tiprankstipranks
Trending News
More News >
Bluebird bio Inc (BLUE)
:BLUE
US Market

Bluebird Bio (BLUE) Price & Analysis

Compare
Followers

BLUE Stock Chart & Stats

$4.97
$0.00(0.00%)
--

Bluebird Bio News

BLUE FAQ

What was Bluebird bio Inc’s price range in the past 12 months?
Currently, no data Available
What is Bluebird bio Inc’s market cap?
Currently, no data Available
When is Bluebird bio Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bluebird bio Inc’s earnings last quarter?
Currently, no data Available
Is Bluebird bio Inc overvalued?
According to Wall Street analysts Bluebird bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does Bluebird bio Inc pay dividends?
    Bluebird bio Inc does not currently pay dividends.
    What is Bluebird bio Inc’s EPS estimate?
    Bluebird bio Inc’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Bluebird bio Inc have?
    Currently, no data Available
    What happened to Bluebird bio Inc’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Bluebird bio Inc?
    Currently, no hedge funds are holding shares in BLUE
    What is the TipRanks Smart Score and how is it calculated?
    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

      Company Description

      Bluebird bio Inc

      Bluebird Bio, Inc. (BLUE) is a biotechnology company specializing in the development of gene therapies for severe genetic diseases and cancer. The company focuses on developing therapies that address the underlying genetic causes of these conditions, primarily through the use of lentiviral-based gene therapies. Bluebird Bio's core products are designed to treat conditions such as beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

      Ownership Overview

      1.13%98.87%
      Insiders
      1.13%
      Mutual Funds
      ― Other Institutional Investors
      98.87% Public Companies and
      Individual Investors

      Options Prices

      Currently, No data available
      ---
      Popular Stocks